2023年6月21日 · The review aimed to revise the existing FIGO Staging System for Endometrial Cancer in order to incorporate essential new published evidence and improve understanding of the complex nature of endometrial cancers.

Since the publication of the last International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial cancer in 2009, a considerable amount of new information has emerged that better defines the pathology and molecular findings as they relate to the type of endometrial carcinoma.

2023年12月15日 · The high-grade, aggressive histological subtypes with myometrial invasion are now classified as FIGO IIC in the 2023 FIGO staging system, which is comprised of serous, clear cell, high-grade endometrioid, mesonephric-like, gastrointestinal-type mucinous endometrial, undifferentiated carcinomas, and carcinosarcomas.

The updated FIGO staging of endometrial cancer for 2023 incorporates different histologic types, tumour features, and molecular classifications to better reflect the current improved understanding of the complex nature of several endometrial cancer types and …

2023年9月23日 · Conclusions: FIGO2023 m had the best discriminatory ability compared with FIGO2008 and FIGO2023. Even in advanced stages, p53 status was a poor prognostic factor. When feasible, molecular subtypes can be added to the staging criteria to allow better prognostic prediction in all stages.

1 天前 · Objective: We aimed to analyze the impact of stage shifts on disease-free survival and overall survival in patients with uterine carcinosarcoma stratified based on FIGO 2009 and 2023 staging systems. Materials and Methods: A total of forty-five patients diagnosed with uterine carcinosarcoma between 2010 and 2024 were included in the study. Patients were classified and analyzed according to ...

FIGO分期系统是确定子宫内膜癌治疗决策和预测预后的关键工具。 最初于1988年作为纯临床系统推出，2009年进行了重大修订，纳入了提示局部、区域和远处肿瘤扩散的临床病理学因素。

2023年8月21日 · According to FIGO 2023, the 5-year endometrial cancer-specific mortality rate in the new downstaged IA3 group (with low risk ovarian metastases) was 11%, and this was significantly lower than in the new IIIA1 group (with high …

Objective: The International Federation of Gynecology and Obstetrics committee modified the endometrial cancer (EC) staging system based on the histopathological feature and molecular profile. The aim is to evaluate the clinical implications of the new 2023 system compared with the previous 2009 system.

The goals of the new staging system are to better define these prognostic groups and create substages that indicate more appropriate surgical, radiation, and systemic therapies. Methods: The FIGO Women's Cancer Committee appointed a Subcommittee on Endometrial Cancer Staging in October 2021, represented by the authors.